Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Xu Cong Claire 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol NovaBridge Biosciences [NBP] (Last) (First) (Middle) C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See remarks 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) ROCKVILLE, MD 20850 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares(1) 288,266(2) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2021 Employee Share Option (right to buy)	(4)	06/08/2031	Ordinary Shares(1)	22,900(3)	$60.7(3)	D
2022 Employee Share Option (right to buy)	(5)	03/04/2032	Ordinary Shares(1)	43,690(3)	$21.15(3)	D
2023 Employee Share Option (right to buy)	(6)	07/04/2032	Ordinary Shares(1)	57,660(3)	$5.55(3)	D
2024 Employee Share Option (right to buy)	(7)	05/30/2034	Ordinary Shares(1)	146,865(3)(7)	$1.74(3)	D
2024 Employee Share Option (right to buy)	(8)	09/03/2034	Ordinary Shares(1)	52,165(3)	$1.05(3)	D
Restricted Share Units	(9)	(9)	Ordinary Shares(1)	36,716(3)	(9)	D
Restricted Share Units	(10)	(10)	Ordinary Shares(1)	5,405(3)	(10)	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Xu Cong Claire C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400 ROCKVILLE, MD 20850			See remarks

Signatures

/s/ Xi-Yong (Sean) Fu as attorney-in-fact		03/18/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
(2)	Reported securities are represented by 123,594 ADSs.
(3)	Number of underlying securities and exercise price expressed in terms of ADSs.
(4)	The option was granted on July 21, 2021 and is fully vested and exercisable.
(5)	The option was granted on March 4, 2022 and is fully vested and exercisable.
(6)	The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date.
(7)	The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised.
(8)	The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised.
(9)	On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.
(10)	On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date.
Remarks: Senior Vice President, Clinical Development Exhibit List: Ex. 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.